1De Rijk MC,Breteler MM,Graveland GA,et al.Prevalence of Parkinson's disease in the elderly:the Rotterdam Study[J].Neurology,1995,45:2143-2146.
2Zhang ZX,Roman GC,Hong Z,et al.Parkinson' disease in China:prevalencein Beijing,Xi' an and Shanghai[J].Lancent,2005,365:595-597.
3John G,Nutt,Wooten GF.Diagnosis and Initial Management of Parkinson's Disease[J].N Engl J Med,2005,353:1021-1027.
4AHV Schapira.Present and future drug treatment for Parkinson's[J].Neurol.Neurosurg.Psychiatry,2005,76:1472-1478.
5Rascol O,Brooks DJ,Korczyn AD,et al.A five-year study of the incidence of dyskinesia in patients with early Parkinson's disease who were treated with ropinirole or levodopa[J].N Engl J Med,2000,342:1484-1491.
6Holloway RG,Shoulson I,Fahn S,et al.Pramipexole vs levodopa as initial treatment for Parkinson disease:a 4-year randomized controlled trial[J].Arch Neurol,2004,61:1044-1053.
7Pfeiffer RF,A promising new technology for Parkinson's disease[J].Neurology,2005,65(Suppl 1):S6-S10.
8Guttman M,Kish SJ,Furukawa Y.Current concepts in the diagnosis and managementof Parkinson's disease[J].CMAJ,2003,168:293-301.
9Poewe W,Luessi,F.Clinical studies with transdermal rotigotine in early Parkinson's disease[J].Neurology,2005,65(Suppl 1):S11-S14.
10Schapira AHV,Obeso J,Timing of Treatment Initiation in Parkinson's Disease:A Need for Reappraisal[J].Ann Neurol,2006,59:559-562.
9[1]Corona-Morales AA,Castell A,Escobar A,et al.FullereneC 60 and ascorbic acid protect cultured chromaffin cells against levodopa toxicity.J Neurosci Res,2003,71(1):121-126.
10[2]Rascol O,Brooks DJ,Korczyn AD,et al.A five-year study of the incidence of dyskinesia in patients with early Parkinson's disease who were treated with ropinirole or levodopa.N Engl J Med,2000,342:1484-1491.
